Table 2.
Characteristics of the main anti-SARS-CoV-2 vaccines.
| Vaccine | Type | Dose Regimen |
Prevention of Symptomatic Infection, % (95% CI) |
Efficacy against the Omicron Strain | Main Adverse Events |
|---|---|---|---|---|---|
| BNT162b2 | mRNA | 2 doses, 3-week interval | 95.0 (90.3–97.6) [39] | 65.5% (95% CI, 63.9–67.0), 2–4 weeks after two doses; 8.8% (95% CI, 7.0–10.5), ≥25 weeks after two doses [40] | Myalgia, arthralgia, pain in the extremities, nervous system disorder, and headache [41] |
| mRNA-1273 | mRNA | 2 doses, 4-week interval | 93.2 (91.0–94.8) [39] | 20% after the first dose, 42.8% after the second dose, 67.7% after the third dose [42] | Thrombotic complications [43] |
| Ad26.COV2.S | VV | Single dose | 66.5 (55.5–75.1) [44] | Guillain–Barré syndrome and thrombotic complications [43] | |
| AZD1222 | VV | 2 doses, 4-week interval | 67.1 (52.3–77.3) [45] | When assessed five months after the second dose, there was no protective effect against symptomatic Omicron infection after two doses [46] | Disseminated intravascular coagulation, thromboembolic events, injection-site pain, erythema, myalgia, arthralgia, and headache [47] |
| Sputnik V | VV | 2 doses, 3-week interval | 91.1 (83.8–95.1) [48] | The serum titer of neutralizing antibodies to the Omicron variant in patients re-vaccinated with Sputnik Light was statistically comparable to the serum titer of neutralizing antibodies to the B.1.1.1 variant in patients vaccinated with Sputnik V [49] | |
| Sputnik Light | VV | 1 dose | Any injection-site symptoms, injection-site pain, erythema, general symptoms, flu-like syndrome, fatigue, headache, muscle and joint pain, pyrexia, chills, decreased appetite, rash, and dizziness [50] | ||
| BBIBP-CorV | IV | 2 doses, 4-week interval | 78.1 (64.9–86.3) [51] | Injection-site redness and swelling, and fever [52] | |
| CoronaVac | IV | 2 doses, 4-week interval | 83.5 (65.4–92.1) [53] | Pain, erythema, and swelling at the injection-site, as well as weakness, myalgia, nausea, and chills [53] |
|
| Ad5-nCoV | VV | 1 dose | 58 [54] | Thrombosis with thrombocytopenia syndrome, Guillain–Barré syndrome, and anaphylaxis [54] | |
| NVX-CoV2373 | PS | ||||
| BBV152 | IV | 2 doses, 4-week interval [55] |